Wall Street Zen Upgrades ICU Medical (NASDAQ:ICUI) to Strong-Buy

Key Points

• Wall Street Zen upgraded ICU Medical to “strong buy,” adding to generally positive analyst sentiment. The stock has a “Moderate Buy” consensus rating and a $192.80 average price target.
• ICU Medical exceeded quarterly expectations, reporting $2.37 in EPS versus the $1.91 consensus and revenue of $547.9 million versus $533.4 million expected. The company provided fiscal 2026 EPS guidance of $8.60–$9.00.
• Shares rose 10.9% to $184.56, approaching the 52-week high of $192.85, though the stock’s elevated valuation—including a price-to-earnings ratio above 156—leaves limited room for execution disappointments.

ICU Medical (NASDAQ:ICUI - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Saturday.

ICUI has been the subject of several other research reports. Jefferies Financial Group upgraded ICU Medical to a "strong-buy" rating in a research note on Thursday, May 7th. Raymond James Financial reissued a "strong-buy" rating and issued a $200.00 price target on shares of ICU Medical in a report on Friday. Needham & Company LLC raised their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a research report on Friday. Zacks Research cut shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Finally, KeyCorp boosted their price objective on shares of ICU Medical from $164.00 to $182.00 and gave the company an "overweight" rating in a research note on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, ICU Medical has an average rating of "Moderate Buy" and a consensus target price of $192.80.

ICU Medical Trading Up 10.9%

Shares of ICUI stock opened at $184.56 on Friday. The company's fifty day simple moving average is $151.64 and its two-hundred day simple moving average is $141.02. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. ICU Medical has a 1 year low of $107.00 and a 1 year high of $192.85. The stock has a market capitalization of $4.61 billion, a price-to-earnings ratio of 156.41, a PEG ratio of 2.32 and a beta of 0.74.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million during the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a return on equity of 7.94% and a net margin of 1.39%.The business's revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the company earned $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, analysts anticipate that ICU Medical will post 6.51 earnings per share for the current year.

Insider Transactions at ICU Medical

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the company's stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the transaction, the director directly owned 7,960 shares in the company, valued at $978,363.60. This represents a 23.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the firm's stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares in the company, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ICU Medical

Several hedge funds have recently bought and sold shares of the stock. Hilton Head Capital Partners LLC bought a new position in shares of ICU Medical in the 4th quarter worth $32,000. Covestor Ltd lifted its holdings in shares of ICU Medical by 22.1% during the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier's stock worth $99,000 after acquiring an additional 126 shares during the last quarter. Strs Ohio lifted its holdings in shares of ICU Medical by 60.0% during the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier's stock worth $114,000 after acquiring an additional 300 shares during the last quarter. Rockefeller Capital Management L.P. grew its position in ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier's stock worth $117,000 after acquiring an additional 146 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in ICU Medical in the fourth quarter worth $120,000. 96.10% of the stock is currently owned by institutional investors.

Key ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source